Newsroom

The world is taking notice of Neuron23's breakthrough science. Take a look.

For Media Relations

If you're a member of the media or analyst community and would like to speak with the Neuron23 team, please get in touch with us.

Greig Communications

kathy@greigcommunications.com

Neuron23 Appoints Sam Jackson, M.D., MBA, as Chief Medical Officer

Read Full Story

In the News

  • NEWS /

    Neuron23 Appoints Sam Jackson, M.D., MBA, as Chief Medical Officer

    Longtime clinical development leader will help advance pipeline of precision medicines for genetically defined neurological and immunological diseases, with initial focus on Parkinson’s disease SOUTH SAN FRANCISCO, Calif., April 12, 2022 – Neuron23™ Inc., an early stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases, today announced the appointment […]

    Read More
  • NEWS /

    Neuron23 Closes $100 Million Series C Financing Round, Nominates Clinical Candidate for Parkinson’s Disease

    SoftBank Vision Fund 2 leads round with participation from all existing investors . Company expects to bring LRRK2 candidate into the clinic for Parkinson’s disease by end of 2022. Valentin Barsan, M.D., and Jim Scopa join Neuron23 board of directors

    Read More
  • NEWS /

    Neuron23™ Closes $113.5 Million Series A And B Financing Led By Westlake Village BioPartners, Kleiner Perkins, And Redmile Group

    Biotechnology company launches to accelerate development of precision medicines for genetically defined neurological and immunological diseases

    Read More